Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Partnership Established to Decode Bowel Disease

By BiotechDaily International staff writers
Posted on 25 Aug 2014
23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity, and response to treatments for IBD.

Approximately 1.4 million people in the United States alone suffer from IBD, according to estimates from the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA). Although IBD is known to be more common in developed countries, the exact cause of this chronic disorder is still not determined, and there is no cure.

The collaboration represents a novel effort for both companies designed to study the underlying genetics of IBD and it is hoped that the project will in the end lead to possible new or optimized treatments for IBD. “We are excited to team up with Pfizer to take an innovative, consumer-centered approach to try to understand the fundamentals of inflammatory bowel disease and the variability of treatment response,” said 23andMe CEO and co-founder Anne Wojcicki.

“Pfizer is committed to bringing forward new treatments for patients suffering with IBD,” said Jose Carlos Gutierrez-Ramos, senior vice president, biotherapeutics research and development, Pfizer. “By enhancing our understanding of the underlying biology of the disease, we hope to better support our clinical research activities and development programs.”

About 23andMe 23andMe helps individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company’s Personal Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits.

Related Links:

23andMe
Pfizer



Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.